stars 1 stars 2 stars 3

About ViaCyte ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates. About ViaCyte’s Pipeline The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCyte’s PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.

View Top Employees from ViaCyte
Revenue $22.6 million
Funding $192.2 million
Employees 88 (88 on RocketReach)
Founded 1999
Address 3550 General Atomics Ct, San Diego, California 92121, US
Phone (858) 455-3708
Fax (858) 207-5001
JavaScript, HTML, PHP +19 more (view full list)
Category Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Health Care, Therapeutics
Web Rank 3 Million
Keywords viacyte, pec-direct™., pec-direct, vc01 encaptra, vialyte vc-01
Competitors BlueRock Therapeutics, Capricor Therapeutics, Inc., Lorem Cytori USA, Inc, SQZ Biotechnologies, SanBio
SIC 873, 87
NAICS 5417, 54171, 541714, 541, 54

ViaCyte Questions

The ViaCyte annual revenue was $22.6 million in 2023.

Rich Wang is the Vice President Clinical Operations of ViaCyte.

88 people are employed at ViaCyte.

ViaCyte is based in San Diego, California.

The NAICS codes for ViaCyte are [5417, 54171, 541714, 541, 54].

The SIC codes for ViaCyte are [873, 87].

Top ViaCyte Employees

View Similar People
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups / month.
Search over 700 million verified professionals across 35 million companies.
Get Contact Info
Get contact details including emails and phone numbers (business & personal).
High Performer Summer 2022 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2
G2Crowd Trusted
300K+ Plugin Users